FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL										
	OMB Number:	3235-0287									
	Estimated average I	ourden									
- 1	hours nor reasons	. 0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>David Nathaniel E</u>					2. Issuer Name and Ticker or Trading Symbol Unity Biotechnology, Inc. [UBX]							(Ch	Relationship of eck all applic	cable) or	Perso	10% Ow	ner
(Last) (First) (Middle) C/O UNITY BIOTECHNOLOGY, INC.					3. Date of Earliest Transaction (Month/Day/Year) 01/29/2021								Officer below)	(give title		Other (s below)	pecify
285 EAST GRAND AVENUE				A MANUAL PARA CONTROL Filed (Manual P. 24)							0.1	6 Individual or Joint/Croup Filing (Chook Assissable					
(Street) SOUTH SAN FRANCISCO CA 94080			4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	ndividual or Joint/Group Filing (Check Applicable) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			Transaction te onth/Day/Y	Execution Date,		Code (Instr. 5)			tr. 3, 4 and	Beneficia Owned F Reported	es Form ally (D) o Following (I) (Ir		m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	Amo	unt	(A) or (D)	Price		action(s) 3 and 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		nd	7. Title and Amor of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expirati Date	ion	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$5.98	01/29/2021		A		50,000		(1)	01/28/20	031	Common Stock	50,000	\$0.00	50,000		D	

Explanation of Responses:

1. The underlying shares vest and become exercisable in 36 successive, equal monthly installments on each monthly anniversary of January 1, 2021, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Remarks:

/s/ Nathaniel E. David

02/02/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.